Skip to main content

Table 5 Prognostic factors in univariate analysis for progression free survival (PFS) and Overall Survival (OS). Data reported are the median survival time for the various groups and the statistical significance

From: Can advanced new radiation therapy technologies improve outcome of high grade glioma (HGG) patients? analysis of 3D-conformal radiotherapy (3DCRT) versus volumetric-modulated arc therapy (VMAT) in patients treated with surgery, concomitant and adjuvant chemo-radiotherapy

 

3DCRT

p

VMAT

p

Overall survival

 Agea

a: 1.33 ± 0.09

b: 1.06 ± 0.19

0.04

a: 1.59 ± 0.23

b: 1.25 ± 0.21

0.12

 KPSb

a: 1.06 ± 0.50

b: 2.03 ± 0.53

<0.001

a: 1.03 ± 0.09

b: 2.95 ± 0.51

<0.001

 Histologyc

a: 3.11 ± 0.60

b: 1.11 ± 0.06

<0.001

a: 3.62 ± 0.39

b: 1.25 ± 0.09

<0.001

 EORd

a: 1.82 ± 0.31

b: 1.02 ± 0.04

<0.001

a: 2.68 ± 0.44

b: 1.19 ± 0.12

<0.001

 MGMTe

a: 1.19 ± 0.06

b: 1.48 ± 0.45

0.002

a: 1.23 ± 0.13

b: 1.99 ± 0.27

0.009

Progression free survival

 Agea

a: 1.10 ± 0.11

b: 0.82 ± 0.25

0.02

a: 1.37 ± 0.24

b: 0.97 ± 0.08

0.06

 KPSb

a: 0.86 ± 0.04

b: 2.01 ± 0.44

<0.001

a: 0.83 ± 0.09

b: 2.78 ± 0.59

<0.001

 Histologyc

a: 2.77 ± 0.57

b: 0.93 ± 0.05

<0.001

a: 3.51 ± 0.42

b: 0.99 ± 0.09

<0.001

 EORd

a: 1.68 ± 0.34

b: 0.83 ± 0.06

<0.001

a: 2.58 ± 0.5

b: 0.92 ± 0.16

<0.001

 MGMTe

a: 0.95 ± 0.04

b: 1.40 ± 0.36

0.02

a: 0.98 ± 0.12

b: 1.70 ± 0.44

0.02

  1. Abbreviations: 3DCRT 3 dimensional conformal radiotherapy, VMAT volumetric modulated arc therapy
  2. aa:<70 or b:>70 years
  3. ba:<80 vs b:>80
  4. ca: Grade III glioma(anaplastic astrocytoma, Anaplastic oligodendroglioma, anaplastic oligoastrocytoma) vs b: Glioblastoma
  5. da: Gross total resection vs b: Partial resection or biopsy
  6. ea: MGMT negative or b: positive